Found: 67
Select item for more details and to access through your institution.
Pramlintide reduced markers of oxidative stress in the postprandial period in patients with type 2 diabetes.
- Published in:
- Diabetes/Metabolism Research & Reviews, 2008, v. 24, n. 2, p. 103, doi. 10.1002/dmrr.765
- By:
- Publication type:
- Article
Tirzepatide Improved Markers of Islet Cell Function and Insulin Sensitivity in People With T2D (SURPASS-2).
- Published in:
- Journal of Clinical Endocrinology & Metabolism, 2024, v. 109, n. 7, p. 1745, doi. 10.1210/clinem/dgae038
- By:
- Publication type:
- Article
Results of a Study Comparing Glycated Albumin to Other Glycemic Indices.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Clinical trial: Effects of pegozafermin on the liver and on metabolic comorbidities in subjects with biopsy‐confirmed nonalcoholic steatohepatitis.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2023, v. 58, n. 10, p. 1005, doi. 10.1111/apt.17709
- By:
- Publication type:
- Article
Pramlintide in the management of insulin-using patients with type 2 and type 1 diabetes.
- Published in:
- 2006
- By:
- Publication type:
- journal article
Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trial.
- Published in:
- Diabetologia, 2020, v. 63, n. 3, p. 473, doi. 10.1007/s00125-019-05065-8
- By:
- Publication type:
- Article
Cardiovascular efficacy and safety of antidiabetic agents: A network meta‐analysis of randomized controlled trials.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 12, p. 3560, doi. 10.1111/dom.15251
- By:
- Publication type:
- Article
Tolerability, safety and pharmacodynamics of oral, small‐molecule glucagon‐like peptide‐1 receptor agonist danuglipron for type 2 diabetes: A 12‐week, randomized, placebo‐controlled, Phase 2 study comparing different dose‐escalation schemes
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 10, p. 2805, doi. 10.1111/dom.15168
- By:
- Publication type:
- Article
A microbiome‐targeting fibre‐enriched nutritional formula is well tolerated and improves quality of life and haemoglobin A1c in type 2 diabetes: A double‐blind, randomized, placebo‐controlled trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 5, p. 1203, doi. 10.1111/dom.14967
- By:
- Publication type:
- Article
A 96‐week, double‐blind, randomized controlled trial comparing bexagliflozin to glimepiride as an adjunct to metformin for the treatment of type 2 diabetes in adults.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 1, p. 293, doi. 10.1111/dom.14875
- By:
- Publication type:
- Article
iGlarLixi versus basal plus Rapid‐Acting insulin in adults with type 2 diabetes advancing from basal insulin therapy: The SoliSimplify Real‐World study.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 1, p. 68, doi. 10.1111/dom.14844
- By:
- Publication type:
- Article
Long‐term effects of dapagliflozin plus saxagliptin versus glimepiride on a background of metformin in patients with type 2 diabetes: Results of a 104‐week extension to a 52‐week randomized, phase 3 study and liver fat MRI substudy.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 1, p. 61, doi. 10.1111/dom.14548
- By:
- Publication type:
- Article
Glycaemic efficacy of an expanded dose range of dulaglutide according to baseline glycated haemoglobin (HbA1c) subgroup: Post hoc analysis of AWARD‐11.
- Published in:
- Diabetes, Obesity & Metabolism, 2021, v. 23, n. 12, p. 2819, doi. 10.1111/dom.14533
- By:
- Publication type:
- Article
Efficacy and safety of dulaglutide 3.0 and 4.5 mg in patients aged younger than 65 and 65 years or older: Post hoc analysis of the AWARD‐11 trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2021, v. 23, n. 10, p. 2279, doi. 10.1111/dom.14469
- By:
- Publication type:
- Article
Effect of dulaglutide 3.0 and 4.5 mg on weight in patients with type 2 diabetes: Exploratory analyses of AWARD‐11.
- Published in:
- Diabetes, Obesity & Metabolism, 2021, v. 23, n. 10, p. 2242, doi. 10.1111/dom.14465
- By:
- Publication type:
- Article
Efficacy and safety of dual add‐on therapy with dapagliflozin plus saxagliptin versus glimepiride in patients with poorly controlled type 2 diabetes on a stable dose of metformin: Results from a 52‐week, randomized, active‐controlled trial
- Published in:
- Diabetes, Obesity & Metabolism, 2020, v. 22, n. 7, p. 1083, doi. 10.1111/dom.13997
- By:
- Publication type:
- Article
Impact of baseline characteristics and beta‐cell function on the efficacy and safety of subcutaneous once‐weekly semaglutide: A patient‐level, pooled analysis of the SUSTAIN 1‐5 trials.
- Published in:
- Diabetes, Obesity & Metabolism, 2020, v. 22, n. 3, p. 303, doi. 10.1111/dom.13896
- By:
- Publication type:
- Article
Hormone‐substrate changes with exenatide plus dapagliflozin versus each drug alone: The randomized, active‐controlled DURATION‐8 study.
- Published in:
- Diabetes, Obesity & Metabolism, 2020, v. 22, n. 1, p. 99, doi. 10.1111/dom.13870
- By:
- Publication type:
- Article
Comparable glycaemic control and hypoglycaemia in adults with type 2 diabetes after initiating insulin glargine 300 units/mL or insulin degludec: The DELIVER Naïve D real‐world study.
- Published in:
- Diabetes, Obesity & Metabolism, 2019, v. 21, n. 9, p. 2123, doi. 10.1111/dom.13793
- By:
- Publication type:
- Article
Efficacy and safety of an expanded dulaglutide dose range: A phase 2, placebo‐controlled trial in patients with type 2 diabetes using metformin.
- Published in:
- Diabetes, Obesity & Metabolism, 2019, v. 21, n. 9, p. 2048, doi. 10.1111/dom.13764
- By:
- Publication type:
- Article
Double‐blind, randomized clinical trial assessing the efficacy and safety of early initiation of sitagliptin during metformin uptitration in the treatment of patients with type 2 diabetes: The CompoSIT‐M study.
- Published in:
- Diabetes, Obesity & Metabolism, 2019, v. 21, n. 5, p. 1128, doi. 10.1111/dom.13626
- By:
- Publication type:
- Article
Comparison of healthcare resource utilization and costs in patients with type 2 diabetes initiating dapagliflozin versus sitagliptin.
- Published in:
- Diabetes, Obesity & Metabolism, 2019, v. 21, n. 2, p. 227, doi. 10.1111/dom.13502
- By:
- Publication type:
- Article
Effect of exenatide QW or placebo, both added to titrated insulin glargine, in uncontrolled type 2 diabetes: The DURATION‐7 randomized study.
- Published in:
- Diabetes, Obesity & Metabolism, 2018, v. 20, n. 7, p. 1602, doi. 10.1111/dom.13266
- By:
- Publication type:
- Article
Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly alone, or dapagliflozin alone added to metformin monotherapy in subgroups of patients with type 2 diabetes in the DURATION‐8 randomized controlled trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2018, v. 20, n. 6, p. 1520, doi. 10.1111/dom.13296
- By:
- Publication type:
- Article
Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly, or dapagliflozin, added to metformin monotherapy, on body weight, systolic blood pressure, and triglycerides in patients with type 2 diabetes in the DURATION‐8 study.
- Published in:
- Diabetes, Obesity & Metabolism, 2018, v. 20, n. 6, p. 1515, doi. 10.1111/dom.13206
- By:
- Publication type:
- Article
Exenatide once weekly improved 24-hour glucose control and reduced glycaemic variability in metformin-treated participants with type 2 diabetes: a randomized, placebo-controlled trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2017, v. 19, n. 1, p. 40, doi. 10.1111/dom.12763
- By:
- Publication type:
- Article
Fatty Acid-Induced Insulin Resistance: Decreased Muscle PI3K Activation But Unchanged Akt Phosphorylation.
- Published in:
- Journal of Clinical Endocrinology & Metabolism, 2002, v. 87, n. 1, p. 226, doi. 10.1210/jcem.87.1.8187
- By:
- Publication type:
- Article
Tirzepatide vs Insulin Lispro Added to Basal Insulin in Type 2 Diabetes: The SURPASS-6 Randomized Clinical Trial.
- Published in:
- JAMA: Journal of the American Medical Association, 2023, v. 330, n. 17, p. 1631, doi. 10.1001/jama.2023.20294
- By:
- Publication type:
- Article
Efficacy and Safety of Oral Small Molecule Glucagon-Like Peptide 1 Receptor Agonist Danuglipron for Glycemic Control Among Patients With Type 2 Diabetes: A Randomized Clinical Trial.
- Published in:
- JAMA Network Open, 2023, v. 6, n. 5, p. e2314493, doi. 10.1001/jamanetworkopen.2023.14493
- By:
- Publication type:
- Article
Safety of Once-weekly Glucagon-like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Metabolic effects of troglitazone therapy in type 2 diabetic, obese, and lean normal subjects.
- Published in:
- 2000
- By:
- Publication type:
- journal article
Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Pharmacokinetics of an Oral Drug (Acetaminophen) Administered at Various Times Relative to Subcutaneous Injection of Pramlintide in Subjects With Type 2 Diabetes.
- Published in:
- Journal of Clinical Pharmacology, 2007, v. 47, n. 7, p. 798, doi. 10.1177/0091270007300949
- By:
- Publication type:
- Article
Decreased susceptibility to fatty acid-induced peripheral tissue insulin resistance in women.
- Published in:
- 2001
- By:
- Publication type:
- journal article
Gastrointestinal Tolerability of Once-Weekly Dulaglutide 3.0 mg and 4.5 mg: A Post Hoc Analysis of the Incidence and Prevalence of Nausea, Vomiting, and Diarrhea in AWARD-11.
- Published in:
- Diabetes Therapy, 2021, v. 12, n. 10, p. 2783, doi. 10.1007/s13300-021-01140-9
- By:
- Publication type:
- Article
Correction to: Safety and Efficacy of Exenatide Once Weekly in Participants with Type 2 Diabetes and Stage 2/3 Chronic Kidney Disease.
- Published in:
- 2020
- By:
- Publication type:
- Correction Notice
Safety and Efficacy of Exenatide Once Weekly in Participants with Type 2 Diabetes and Stage 2/3 Chronic Kidney Disease.
- Published in:
- Diabetes Therapy, 2020, v. 11, n. 7, p. 1467, doi. 10.1007/s13300-020-00815-z
- By:
- Publication type:
- Article
A Review of the Safety and Adverse Event Profile of the Fixed-Ratio Combination of Insulin Glargine and Lixisenatide.
- Published in:
- Diabetes Therapy, 2019, v. 10, n. 1, p. 21, doi. 10.1007/s13300-018-0547-5
- By:
- Publication type:
- Article
Improved glycemic control with minimal systemic metformin exposure: Effects of Metformin Delayed-Release (Metformin DR) targeting the lower bowel over 16 weeks in a randomized trial in subjects with type 2 diabetes.
- Published in:
- PLoS ONE, 2018, v. 13, n. 9, p. 1, doi. 10.1371/journal.pone.0203946
- By:
- Publication type:
- Article
Once-Weekly Basal Insulin Fc Demonstrated Similar Glycemic Control to Once-Daily Insulin Degludec in Insulin-Naive Patients With Type 2 Diabetes: A Phase 2 Randomized Control Trial.
- Published in:
- Diabetes Care, 2023, v. 46, n. 5, p. 1060, doi. 10.2337/dc22-2396
- By:
- Publication type:
- Article
Changes in Glucose Metabolism and Glycemic Status With Once-Weekly Subcutaneous Semaglutide 2.4 mg Among Participants With Prediabetes in the STEP Program.
- Published in:
- Diabetes Care, 2022, v. 45, n. 10, p. 2396, doi. 10.2337/dc21-1785
- By:
- Publication type:
- Article
Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11).
- Published in:
- 2021
- By:
- Publication type:
- journal article
Randomized Double-Blind Clinical Trial Comparing Ultra Rapid Lispro With Lispro in a Basal-Bolus Regimen in Patients With Type 2 Diabetes: PRONTO-T2D.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Efficacy and Safety Over 2 Years of Exenatide Plus Dapagliflozin in the DURATION-8 Study: A Multicenter, Double-Blind, Phase 3, Randomized Controlled Trial.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Efficacy and Safety of the Glucagon Receptor Antagonist RVT-1502 in Type 2 Diabetes Uncontrolled on Metformin Monotherapy: A 12-Week Dose-Ranging Study.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Safety and Efficacy of Exenatide Once Weekly Plus Dapagliflozin Once Daily Versus Exenatide or Dapagliflozin Alone in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy: 52-Week Results of the DURATION-8 Randomized Controlled Trial.
- Published in:
- 2018
- By:
- Publication type:
- journal article
More Similarities Than Differences Testing Insulin Glargine 300 Units/mL Versus Insulin Degludec 100 Units/mL in Insulin-Naive Type 2 Diabetes: The Randomized Head-to-Head BRIGHT Trial.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Review of Adverse Events Associated With False Glucose Readings Measured by GDH-PQQ-Based Glucose Test Strips in the Presence of Interfering Sugars.
- Published in:
- Diabetes Care, 2010, v. 33, n. 4, p. 728, doi. 10.2337/dc09-1822
- By:
- Publication type:
- Article
Two‐year effect of semaglutide 2.4 mg on control of eating in adults with overweight/obesity: STEP 5.
- Published in:
- Obesity (19307381), 2023, v. 31, n. 3, p. 703, doi. 10.1002/oby.23673
- By:
- Publication type:
- Article
192-OR: Glycemic Control with Once-Weekly Basal Insulin Fc (BIF) in Persons with Type 2 Diabetes Mellitus (T2DM) Using Continuous Glucose Monitoring (CGM) in a Phase 2 Study.
- Published in:
- Diabetes, 2021, v. 70, p. N.PAG, doi. 10.2337/db21-192-OR
- By:
- Publication type:
- Article